Filing Flows › AtriCure (ATRC) › Q3 2026 › vs Q2 2026
AtriCure (ATRC) Q3 2026 vs Q2 2026 (quarter over quarter)
AtriCure's revenue rose $846K (+0.6%) from $154M in Q2 2026 to $154M in Q3 2026. Gross margin 77.3% against 77.2% (+0.0 pts).
AtriCure, Q3 2026: revenue $154M (+15% year over year), operating margin 2.8%, net earnings $4.1M, operating cash flow $30.3M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 77.3% | 77.2% | +0.0 pts |
| Operating margin | 2.8% | 6.3% | -3.5 pts |
| Net margin | 2.6% | 5.8% | -3.2 pts |
| Free cash flow margin | 15.5% | 12.0% | +3.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $154M | $154M | $846K | +0.6% |
| Gross profit | $119M | $119M | $721K | +0.6% |
| Cost of revenue | $35.1M | $35.0M | $125K | +0.4% |
| Operating profit | $4.4M | $9.7M | −$5.3M | -55% |
| Operating expenses | $115M | $109M | $6.0M | +6% |
| Pre-tax earnings | $4.0M | $9.4M | −$5.4M | -57% |
| Research & development | $32.1M | $26.4M | $5.7M | +22% |
| SG&A | $82.9M | $82.6M | $319K | +0.4% |
| Income tax benefit | $47K | −$471K | $518K | — |
| Net earnings | $4.1M | $9.0M | −$4.9M | -55% |
| Depreciation & amortization | $5.5M | $5.3M | $168K | +3% |
| Share-based compensation | $12.5M | $12.3M | $165K | +1% |
| Working capital & other | $8.3M | −$4.4M | $12.7M | — |
| Operating cash flow | $30.3M | $22.2M | $8.1M | +37% |
| Free cash flow (OCF − capex) | $23.9M | $18.4M | $5.5M | +30% |
| Capital expenditures | $6.4M | $3.8M | $2.6M | +70% |
Questions
How much did AtriCure's revenue grow quarter over quarter in Q3 2026?
AtriCure's revenue rose $846K (+0.6%) from $154M in Q2 2026 to $154M in Q3 2026. Gross margin 77.3% against 77.2% (+0.0 pts).